Biopharmaceuticals Market

Executive Summary

Biopharmaceuticals Market was valued at US $419.25 billion in 2021 and is projected to grow at 7.69% CAGR over the forecast period to reach US $654.00 billion by 2027. Biopharmaceuticals Market represented US $57.75 billion opportunity over 2019-2021 and estimated to create US $234.76 billion opportunity in 2027 over 2021.

Biopharmaceuticals from Consainsights analyses the Biopharmaceuticals Market in the Life Sciences industry over the forecast period to 2027.

Biopharmaceuticals research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Biopharmaceuticals segmentation includes Product Type, Therapeutic Application and Geography.

Based on the Product Type, the Biopharmaceuticals analysis covers Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell and Gene Therapies, Synthetic Immunomodulators, Other Product Types.

In Product Type segment, Monoclonal Antibodies segment has highest cagr growth of 6.81%.

Based on the Therapeutic Application, the Biopharmaceuticals analysis covers Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, Other Diseases.

In Therapeutic Application segment, Oncology segment has highest cagr growth of 6.81%.

Based on the region, the Biopharmaceuticals analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Novo Nordisk AS, Pfizer Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Merck Co. & Inc., Sanofi SA, AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Company Limited and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product Type

Introduction

In 2021, Monoclonal Antibodies segment has the highest revenue of US $160.19 billion and is expected to grow at CAGR of 6.81% by 2027 Monoclonal Antibodies segment has highest cagr growth of 6.81%.

Monoclonal Antibodies

Monoclonal Antibodies segment was valued at US $138.12 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $249.89 billion by 2027. Monoclonal Antibodies segment represented US $22.07 billion opportunity over 2019-2021 and estimated to create US $89.70 billion opportunity in 2027 over 2021.

Recombinant Growth Factors

Recombinant Growth Factors segment was valued at US $85.11 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $153.99 billion by 2027. Recombinant Growth Factors segment represented US $13.60 billion opportunity over 2019-2021 and estimated to create US $55.27 billion opportunity in 2027 over 2021.

Purified Proteins

Purified Proteins segment was valued at US $52.45 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $94.89 billion by 2027. Purified Proteins segment represented US $8.38 billion opportunity over 2019-2021 and estimated to create US $34.06 billion opportunity in 2027 over 2021.

Recombinant Proteins

Recombinant Proteins segment was valued at US $33.69 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $60.95 billion by 2027. Recombinant Proteins segment represented US $5.38 billion opportunity over 2019-2021 and estimated to create US $21.88 billion opportunity in 2027 over 2021.

Recombinant Hormones

Recombinant Hormones segment was valued at US $19.45 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $35.19 billion by 2027. Recombinant Hormones segment represented US $3.11 billion opportunity over 2019-2021 and estimated to create US $12.63 billion opportunity in 2027 over 2021.

Vaccines

Vaccines segment was valued at US $13.84 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $25.04 billion by 2027. Vaccines segment represented US $2.21 billion opportunity over 2019-2021 and estimated to create US $8.99 billion opportunity in 2027 over 2021.

Recombinant Enzymes

Recombinant Enzymes segment was valued at US $8.13 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $14.71 billion by 2027. Recombinant Enzymes segment represented US $1.30 billion opportunity over 2019-2021 and estimated to create US $5.28 billion opportunity in 2027 over 2021.

Cell and Gene Therapies

Cell and Gene Therapies segment was valued at US $4.96 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $8.97 billion by 2027. Cell and Gene Therapies segment represented US $0.79 billion opportunity over 2019-2021 and estimated to create US $3.22 billion opportunity in 2027 over 2021.

Synthetic Immunomodulators

Synthetic Immunomodulators segment was valued at US $4.15 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $7.51 billion by 2027. Synthetic Immunomodulators segment represented US $0.66 billion opportunity over 2019-2021 and estimated to create US $2.69 billion opportunity in 2027 over 2021.

Other Product Types

Other Product Types segment was valued at US $1.59 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $2.88 billion by 2027. Other Product Types segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $1.03 billion opportunity in 2027 over 2021.

Therapeutic Application

Introduction

In 2021, Oncology segment has the highest revenue of US $166.69 billion and is expected to grow at CAGR of 6.81% by 2027 Oncology segment has highest cagr growth of 6.81%.

Oncology

Oncology segment was valued at US $143.73 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $260.03 billion by 2027. Oncology segment represented US $22.96 billion opportunity over 2019-2021 and estimated to create US $93.34 billion opportunity in 2027 over 2021.

Inflammatory and Infectious Diseases

Inflammatory and Infectious Diseases segment was valued at US $87.79 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $158.83 billion by 2027. Inflammatory and Infectious Diseases segment represented US $14.03 billion opportunity over 2019-2021 and estimated to create US $57.01 billion opportunity in 2027 over 2021.

Autoimmune Disorders

Autoimmune Disorders segment was valued at US $52.25 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $94.52 billion by 2027. Autoimmune Disorders segment represented US $8.35 billion opportunity over 2019-2021 and estimated to create US $33.93 billion opportunity in 2027 over 2021.

Metabolic Disorders

Metabolic Disorders segment was valued at US $34.06 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $61.62 billion by 2027. Metabolic Disorders segment represented US $5.44 billion opportunity over 2019-2021 and estimated to create US $22.12 billion opportunity in 2027 over 2021.

Hormonal Disorders

Hormonal Disorders segment was valued at US $23.74 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $42.95 billion by 2027. Hormonal Disorders segment represented US $3.79 billion opportunity over 2019-2021 and estimated to create US $15.42 billion opportunity in 2027 over 2021.

Cardiovascular Diseases

Cardiovascular Diseases segment was valued at US $9.71 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $17.56 billion by 2027. Cardiovascular Diseases segment represented US $1.55 billion opportunity over 2019-2021 and estimated to create US $6.30 billion opportunity in 2027 over 2021.

Neurological Diseases

Neurological Diseases segment was valued at US $5.15 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $9.32 billion by 2027. Neurological Diseases segment represented US $0.82 billion opportunity over 2019-2021 and estimated to create US $3.35 billion opportunity in 2027 over 2021.

Other Diseases

Other Diseases segment was valued at US $5.07 billion in 2019 and is projected to grow at 6.81% CAGR over the forecast period to reach US $9.18 billion by 2027. Other Diseases segment represented US $0.81 billion opportunity over 2019-2021 and estimated to create US $3.29 billion opportunity in 2027 over 2021.